

## Brukinsa® (zanubrutinib) - New indication

- On January 19, 2023, <u>BeiGene announced</u> the FDA approval of <u>Brukinsa (zanubrutinib)</u>, for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
- Brukinsa is also approved for the treatment of mantle cell lymphoma, Waldenström's macroglobulinemia, and marginal zone lymphoma.
- The approval of Brukinsa for the new indication was based on two randomized trials (SEQUOIA and ALPINE). SEQUOIA was an open-label study in patients with previously untreated CLL/SLL. Patients without 17p deletion (17p del) were randomized to receive either Brukinsa until disease progression or unacceptable toxicity (n = 241) or bendamustine plus rituximab (BR) for 6 cycles (n = 238). Additionally, the same Brukinsa regimen was evaluated in 110 patients with previously untreated, 17p del CLL/SLL in a non-randomized cohort. Efficacy was based on progression-free survival (PFS) in the randomized cohort and overall response rate (ORR) and duration of response (DOR) in the single-arm cohort.
  - In the randomized cohort, median PFS was not estimable for the Brukinsa arm vs. 33.7 months for the BR treatment arm (hazard ratio 0.42, 95% CI: 0.28, 0.63; p < 0.0001). The ORR was 93% (95% CI: 89, 96) for the Brukinsa arm vs. 85% (95% CI: 80, 90) for the BR arm. At the time of analysis, overall survival (OS) data were immature.</p>
  - In the single-arm cohort, the ORR was 88% (95% CI: 81, 94). The median DOR was not estimable.
- ALPINE was a randomized, open-label, actively controlled study in 652 patients with relapsed or refractory CLL/SLL. Patients were randomized to receive either Brukinsa or <u>Imbruvica® (ibrutinib)</u>, each administered until disease progression or unacceptable toxicity. Efficacy was based on ORR and DOR.
  - The ORR was 80% and 73% for Brukinsa and Imbruvica, respectively (response rate ratio 1.10, 95% CI: 1.01, 1.20; p = 0.0264).
  - The median DOR was not estimable for either treatment arm.
  - At the time of analysis, OS data were immature.
- The recommended dosage of Brukinsa for all its uses is 160 mg taken orally twice daily or 320 mg taken orally once daily until disease progression or unacceptable toxicity.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.